Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected shareholders between March 10, 2024, and September 29, 2025 [3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding their drug candidate SLK, asserting that it would not provide superior clinical benefits compared to BIMZELX, and that its supposed advantages in tissue penetration would not lead to clinical efficacy [4]. - The complaint highlights that the defendants lacked a reasonable basis for their positive statements about SLK's superiority over traditional monoclonal antibodies [4]. Group 2: Investor Information - Shareholders who experienced losses during the specified timeframe are encouraged to seek recovery, regardless of whether they still hold their shares [5]. - Levi & Korsinsky LLP, the firm handling the case, has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [6].

Core Points - A class action securities lawsuit has been filed against Avantor, Inc. to recover losses for shareholders affected by alleged securities fraud between March 5, 2024, and October 28, 2025 [2] - The complaint alleges that Avantor's competitive positioning was misrepresented, indicating that the company was facing negative impacts from increased competition, which rendered the defendants' statements about the company's business and prospects materially false and misleading [3] Company Information - Avantor, Inc. is currently facing legal challenges due to claims of securities fraud, which may impact its reputation and stock performance [2][3] - The lawsuit highlights concerns regarding the company's competitive positioning and operational challenges, which could affect investor confidence and future performance [3] Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the shareholders in this case, emphasizing their extensive experience and success in securing recoveries for aggrieved investors [5]

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. to recover losses for shareholders affected by alleged securities fraud between June 20, 2025, and September 24, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit alleges that CarMax's defendants made false statements and concealed information regarding the company's growth prospects, claiming that the growth was overstated and primarily driven by temporary factors related to customer behavior influenced by tariff speculation [3]. - The complaint asserts that the statements made by the defendants about CarMax's business operations and future prospects were materially false and misleading, lacking a reasonable basis during the relevant time [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses in CarMax, Inc. stock during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - A class action lawsuit has been filed against V.F. Corporation, alleging securities fraud that negatively impacted shareholders between October 30, 2023, and May 20, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that V.F. Corporation made materially false and misleading statements regarding its turnaround plans, particularly concerning the Vans brand, which required significant reset actions to return to growth [3]. - The lawsuit highlights that the true state of Vans' revenue growth trajectory was concealed, leading to significant setbacks [3]. Group 2: Financial Impact - On May 21, 2025, V.F. Corporation reported a significant decline in Vans' growth, with losses worsening from an 8% decline in the previous quarter to a 20% decline in the fourth quarter [4]. - The company attributed its disappointing results to deliberate actions taken to eliminate unprofitable businesses, which were previously unannounced, and indicated that even without these actions, Vans would have experienced a "high single digit" revenue decline [4]. - Following the announcement, V.F. Corporation's stock price dropped from $14.43 per share on May 20, 2025, to $12.15 per share on May 21, 2025, marking a decline of approximately 15.8% in one day [4].

Core Viewpoint - A class action securities lawsuit has been filed against Fluor Corporation, alleging securities fraud that negatively impacted shareholders between February 18, 2025, and July 31, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that Fluor Corporation made false statements and concealed significant issues related to costs associated with infrastructure projects, including subcontractor design errors, price increases, and scheduling delays [3]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, had a substantial negative impact on the company's business and financial results [3]. - The complaint further asserts that Fluor's financial guidance for FY 2025 was unreliable, the effectiveness of its risk mitigation strategy was overstated, and the impact of economic uncertainty was understated [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated regarding potential class action claims due to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to inflated stock prices and subsequent losses for investors [2][4]. Group 1: Allegations and Misleading Statements - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission timeline and approval process for aficamten, claiming expected FDA approval in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - It was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process, indicating a reckless decision to omit critical information [2]. Group 2: Impact on Shareholders - As a result of the misleading statements, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth about the NDA submission was disclosed [2]. - The deadline for shareholders to register for the class action is November 17, 2025, and there is no cost or obligation to participate [3]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and seeking recovery for losses incurred due to deceitful practices by companies [4]. - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Avantor, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive positioning and business operations during the specified class period [1]. Group 1: Allegations - The complaint claims that Avantor's competitive positioning was weaker than publicly represented by the defendants [1]. - It is alleged that Avantor was negatively affected by increased competition, which was not disclosed [1]. - As a result, the representations made by the defendants about the company's business, operations, and prospects were materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is from March 5, 2024, to October 28, 2025 [1]. - Shareholders are encouraged to register for the class action by December 29, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm is committed to ensuring companies adhere to responsible business practices and good corporate citizenship [3]. - The firm seeks recovery for investors who incurred losses due to false or misleading statements that led to artificial inflation of stock prices [3].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1][2]. Summary by Sections Allegations - The complaint alleges that aTyr Pharma made overwhelmingly positive statements about Efzofitimod while concealing material adverse facts about the drug's efficacy, particularly its ability to allow patients to taper steroid usage completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically in the change from baseline in mean daily OSC dose at week 48 [1]. Stock Price Impact - Following the announcement of the disappointing study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2].

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc, alleging securities fraud that affected shareholders between May 16, 2024, and August 5, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that Marex Group plc made false statements and concealed information regarding the inflation of its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [3]. - As a result of these actions, the positive statements made by the defendants about the company's business and prospects were materially false and misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [5].

New York, New York--(Newsfile Corp. - November 10, 2025) - If you suffered a loss on your Baxter International, Inc. (NYSE: BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=176438&wire=5&utm_campaign=23or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder a ...